Latest Thesis
United Therapeutics: the rare-disease cash engine has to outrun concentration risk
United Therapeutics is a profitable rare-disease biotech with an unusually strong cash baseline. The hard question is not whether the company currently earns money; it is whether pulmonary hypertension concentration, lifecycle management and pipeline investment can keep compounding without a product-cycle break.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
Recent Reports
Compact report index for this company.
ReportTypeUpdatedReadActions
United Therapeutics: the rare-disease cash engine has to outrun concentration riskUnited Therapeutics is a profitable rare-disease biotech with an unusually strong cash baseline. The hard question is not whether the company currently earns money; it is whether pulmonary hypertension concentration, lifecycle management and pipeline investment can keep compounding without a product-cycle break.NASDAQMay 20, 2026Research reportReadSlides